Optimal dose of ramosetron in female patients with irritable bowel syndrome with diarrhea: A randomized, placebo-controlled phase II study.

MLA

Fukudo, S., et al. “Optimal Dose of Ramosetron in Female Patients with Irritable Bowel Syndrome with Diarrhea: A Randomized, Placebo-Controlled Phase II Study.” Neurogastroenterology & Motility, vol. 29, no. 6, June 2017, p. n/a-N.PAG. EBSCOhost, https://doi.org/10.1111/nmo.13023.

APA

Fukudo, S., Matsueda, K., Haruma, K., Ida, M., Hayase, H., Akiho, H., Nakashima, Y., & Hongo, M. (2017). Optimal dose of ramosetron in female patients with irritable bowel syndrome with diarrhea: A randomized, placebo-controlled phase II study. Neurogastroenterology & Motility, 29(6), n/a-N.PAG. https://doi.org/10.1111/nmo.13023

Chicago

Fukudo, S., K. Matsueda, K. Haruma, M. Ida, H. Hayase, H. Akiho, Y. Nakashima, and M. Hongo. 2017. “Optimal Dose of Ramosetron in Female Patients with Irritable Bowel Syndrome with Diarrhea: A Randomized, Placebo-Controlled Phase II Study.” Neurogastroenterology & Motility 29 (6): n/a-N.PAG. doi:10.1111/nmo.13023.